David Porter

ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 7

Top Venues

Cancer chemotherapy and pharmacology

Journal of liposome research

European journal of drug metabolism and pharmacokinetics

Pharmaceutical development and technology

Auckland District Health Board

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Auckland District Health Board

New Zealand

Consultant Medical Oncologist :: Medical Oncology

Auckland District Health Board

New Zealand

Clinical Director :: Medical Oncology

Publications

Yu Gao, Andrew N Shelling, Emma Nolan, David Porter, Euphemia Y Leung, Zimei Wu
Liposome-enabled bufalin and doxorubicin combination therapy for trastuzumab-resistant breast cancer with a focus on cancer stem cells. Journal of liposome research (2024)
Yu Gao, Andrew N Shelling, Emma Nolan, David Porter, Euphemia Y Leung, Zimei Wu
Liposome-enabled bufalin and doxorubicin combination therapy for trastuzumab-resistant breast cancer with a focus on cancer stem cells. Journal of liposome research 34 (3) (2024)
Yu Gao, Andrew N Shelling, David Porter, Euphemia Y Leung, Zimei Wu
Stability of trastuzumab during nanomedicine formulation using SEC-HPLC coupled with polyacrylamide gel electrophoresis. Pharmaceutical development and technology (2023)
Soo Hee Jeong, Ottiniel Chavani, Kathryn Elisa Burns, David Porter, Michael P N Findlay, Nuala Ann Helsby
Severe 5-Fluorouracil-Associated Gastrointestinal Toxicity Unexplained by Dihydropyrimidine Dehydrogenase Deficiency and Renal Impairment: Should We Be Investigating Other Elimination Pathways to Assess the Risk of 5-Fluorouracil Toxicity? European journal of drug metabolism and pharmacokinetics 46 (6) (2021)
Kathryn Elisa Burns, Ottiniel Chavani, Soo Hee Jeong, John A Duley, David Porter, Michael P N Findlay, Robert Matthew Strother, Nuala Ann Helsby
Comparison of a thymine challenge test and endogenous uracil-dihydrouracil levels for assessment of fluoropyrimidine toxicity risk. Cancer chemotherapy and pharmacology 87 (5) (2021)
Nuala Ann Helsby, Minghan Yong, Kathryn Elisa Burns, Michael P N Findlay, David Porter
Cyclophosphamide bioactivation pharmacogenetics in breast cancer patients. Cancer chemotherapy and pharmacology 88 (3) (2021)
Kathryn Elisa Burns, Daniel Allright, David Porter, Michael P N Findlay, Nuala Ann Helsby
A simple ex vivo bioassay for 5-FU transport into healthy buccal mucosal cells. Cancer chemotherapy and pharmacology 84 (4) (2019)

David Porter.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

David Porter